Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors
Roger Perlmutter Resurfaces As CEO Of Eikon, Raises $148m
Executive Summary
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
You may also be interested in...
Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.